Amlodipine Besylate

The aim and objective of the present work is to design and develop fast disintegrating tablets of Amlodipine Besylate to improve the patient compliance and  desired bioavailability by selected delivery system by following immediate release mechanism. The drawbacks of the tablets can be overcome using methods involved in modified dissolving tablets, oral  dissolving  tablets (MDT) or orally disinter grating tablets (ODT) ; which started as an alternative oral dosage forms. To achieve successful delivery of drug , it  needs to be protected from degradation,  drug release to be improved and increase absorption. For this objective and to have the rapid  uptake of drug in solution form by rapid disintegrating formulation to be expected to have better  Therapeutic effect of both drugs in the gastrointestinal tract. The research objective   of the present work understands the novel advancements that are made in oral fast disintegration preparations incorporated anti hypertensive drug like Amlodipine Besylate using combination of super disintegrants.

The manuscript describes validated simultaneous equation method for the simultaneous estimation of Amlodipine Besylate and Indapamide in combined dosage form. Simultaneous equation method was based on the estimation of both the drugs at two wavelengths i.e. absorption maxima of both drugs. An absorption maxima of Amlodipine besylate was 240 nm and absorption maxima of Indapamide was 215 nm in methanol. The linearity was obtained over the concentration range of 10 – 30 µg/mL for amlodipine besylate and 2 – 10 µg/mL for Indapamide with mean recovery of 99.45 ± 0.84 % and 99.46 ± 0.33 % for Amlodipine Besylate and Indapamide, respectively. These methods were found to be simple, sensitive, accurate, precise and economical and applicable for the simultaneous determination of Amlodipine Besylate and Indapamide in combined dosage form.